ClinicalTrials.gg
RecruitingNCT06963606Updated Dec 31, 2025

Effectiveness of Computer-Aided Detection Chest X-Ray Screening for Improving Tuberculosis Diagnostic Yield in Chinese Primary Health Care Settings: Study Protocol for a Prospective Cluster Randomized Controlled Trial

An interventional study of Artificial intelligence-assisted chest X-ray in TB screening and Routine doctors analyze the process of chest X-rays in Tuberculosis (TB), sponsored by Xuelin Yang. Recruiting at 1 site in China. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Xuelin Yang · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22,000
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Tuberculosis with a site in China — 22 open to participants now, 25 under way, 5 of them phase 3. Tuberculosis · China.

Planned enrollment
2nd of 47
22,000 · median 241
Started
2025
with 7 others
No phase
11 of 62
2 open now
Primary completion
2027-12
later than 19 of 24 live
Registered
52nd of 62
by date

Among the 62 studies in Tuberculosis with a site in China, this one is the 2nd largest by planned enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 with no phase, reaches primary completion later than 19 of the 24 other live ones, and was the 52nd registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

22 of the 62 studies in Tuberculosis with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 15 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Tuberculosis with a site in China, or all of them as a file.
02

Study summary

The global incidence rate and mortality of tuberculosis (TB) pose a challenge to achieving the goals set out in the tuberculosis eradication strategy and the SDGs by 2030. At present, timely and accessible early detection methods for tuberculosis are still a major obstacle. In this context, the emergence of artificial intelligence (AI), especially the AI-assisted chest X-ray (CXR) in the field of diagnostic imaging, has proved the potential to significantly improve the speed and accuracy of tuberculosis diagnosis. However, the extent to which these technologies can affect the broader tuberculosis care cascade, especially by reducing the diagnostic time in the population level, has not yet been explored. The proposed project plans to use the certified AI-assisted CXR system (JF CXR-1) for tuberculosis screening, which aims not only to integrate AI into the diagnosis process, but also to critically assess its impact on the overall tuberculosis care cascade. The selected location for this project is Yichang City in western Hubei Province, China, which is facing a high TB burden. The city has established a strong city-wide health big data platform ten years ago, providing the basis for this project. The project will first optimize the AI-assisted CXR system through retrospective imaging to validate the accuracy of case screening (Stage Ⅰ). Secondly, the project will shift its focus to the real world, where cluster randomized controlled trials will be conducted in primary-care settings (Stage Ⅱ). In this stage, the effectiveness of the AI-assisted CXR system in reducing the diagnostic time of TB cases will be evaluated by comparing with those settings without using the tool. In stage Ⅲ, the qualitative and quantitative methods will be used to evaluate the generalization, practicality, and feasibility of extending the screening strategy in various community environments. If the AI-assisted screening strategy is proven accurate, effective, and sustainable, it may pave the way for its widespread adoption in primary healthcare institutions and other grassroots areas in China. This can not only improve the timeliness of tuberculosis diagnosis, but also help to allocate medical resources more effectively and significantly reduce tuberculosis-related incidence and mortality, bringing positive changes to global public health. In addition, the results of the project can also provide information for policy decisions and guide the formulation of strategies to prioritize the integration of AI into health care, which can not only fight against tuberculosis but also a series of other diseases.

Read the detailed description

Research Plan

  1. Questionnaire survey - Collect general baseline characteristics The general data characteristics involved in this study include age, gender, marital status, occupation, income, place of residence, lifestyle (smoking, drinking), past medical history, symptom screening, nutritional status, sleep status, mental health status, cognition and acceptance of the application of artificial intelligence in imaging.
  2. Pre-test Before the formal cluster randomized controlled trial, a pre-trial involving 100 residents who met the inclusion and exclusion criteria was conducted in two township medical and health institutions to preliminarily verify its effectiveness through the randomized controlled trial and provide suggestions for the performance and potential adjustments of the artificial intelligence-assisted CXR system before the comprehensive trial.
  3. Cluster randomized controlled trial 3.1 Intervention Group The subjects who visited the township medical and health institutions in the intervention group, underwent chest DR Examinations, and signed the informed consent form were included in the intervention group, and the visiting time was recorded.

After the completion of the chest DR Examination, the chest X-ray was analyzed by the artificial intelligence-assisted system (JF CXR-1) to identify the potential signs of tuberculosis. Meanwhile, the doctor analyzed the results of the chest X-ray. After the analysis results were confirmed, the initial judgment results of the doctor and the analysis results of the artificial intelligence-assisted system were recorded, and the reading results of the artificial intelligence-assisted system were fed back to the doctor. Review the doctor's comprehensive analysis results of the artificial intelligence-assisted system, make a final judgment on the chest X-ray results, and determine whether further relevant examinations (such as etiological examination, CT examination, etc.) are needed. Record the doctor's judgment results.

Follow up and record the time of diagnosis reported by the tuberculosis specific disease system.

3.2 Control Group The subjects who visited the township medical and health institutions in the control group, underwent chest DR Examinations, and signed the informed consent form were included in the control group, and the visiting time was recorded.

After the chest DR Examination is completed, a regular doctor reviews the films without using an artificial intelligence-assisted system. Once the results of the regular doctor's review are confirmed, a final judgment is made on whether further related examinations (such as etiological tests, CT scans, etc.) are needed, and the doctor's judgment is recorded.

Follow up and record the time of diagnosis reported by the tuberculosis specific disease system.

03

Conditions studied

  • Tuberculosis (TB)

Browse trials for

Keywords

  • tuberculosis
  • computer-assisted detection
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Eligibility criteria Inclusion criteria

Participants must receive medical treatment at the primary healthcare hospitals in Yichang City, Hubei Province, and underwent chest X-ray examinations. The participants have to meet the following criteria:

  1. >15 years old.
  2. Appearance of tuberculosis-related respiratory symptoms or signs.
  3. Individuals not previous diagnosed with active pulmonary tuberculosis.
  4. Capable of completing pathogen examinations and subsequent related inspections.

Exclusion criteria

Those who meet any of the below criteria will be excluded:

  1. Diagnosed with extrapulmonary tuberculosis or latent tuberculosis infection during the current visit.
  2. The quality of Chest X-ray images did not meet the standard requirements.
  3. Unrecognized identity information participants.

Withdrawal Criteria

  1. Participants who are lost to follow-up or who do not complete the follow-up period.
  2. Participants who experience a sudden and serious illness or choose not to continue participating in the study.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
22,000 participants (estimated)

Study arms

  • Active comparator
    computer-assisted detection

    Diagnostic Test: Artificial intelligence-assisted chest X-ray in TB screening

  • Placebo comparator
    Do not use computer-assisted detection

    Other: Routine doctors analyze the process of chest X-rays

Interventions

  • Diagnostic testArtificial intelligence-assisted chest X-ray in TB screening

    After the completion of the chest DR Examination, the chest X-ray was analyzed by the artificial intelligence-assisted system (JF CXR-1) to identify the potential signs of tuberculosis. Meanwhile, the doctor analyzed the results of the chest X-ray. After the analysis results were confirmed, the initial judgment results of the doctor and the analysis results of the artificial intelligence-assisted system were recorded, and the reading results of the artificial intelligence-assisted system were fed back to the doctor. Review the doctor's comprehensive analysis results of the artificial intelligence-assisted system, make a final judgment on the chest X-ray results, and determine whether further relevant examinations (such as etiological examination, CT examination, etc.) are needed. Record the doctor's judgment results. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system.

  • OtherRoutine doctors analyze the process of chest X-rays

    After the chest DR Examination is completed, a regular doctor reviews the films without using an artificial intelligence-assisted system. Once the results of the regular doctor's review are confirmed, a final judgment is made on whether further related examinations (such as etiological tests, CT scans, etc.) are needed, and the doctor's judgment is recorded. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system

06

What researchers measure

Primary outcomes

  1. The difference in the diagnostic yield of pulmonary tuberculosis screening in township medical and health institutions between the intervention group and the control group.

    Diagnostic yield = The number of people who visited the hospital for chest DR Examination and were ultimately determined to require further relevant examinations and were diagnosed in the tuberculosis specific disease reporting system/the number of people who underwent chest DR Examination

    Time frame: pre-intervention (via retrospective analysis of historical data), post-intervention (six and twelve months after the intervention starts)

Secondary outcomes

  1. The difference in the average number of days from visiting township medical and health institutions to the diagnosis of pulmonary tuberculosis between patients in the intervention group and the control group

    The number of days for confirmed diagnosis = the time of diagnosis reported by the tuberculosis specific disease system - the time of the patient's visit

    Time frame: pre-intervention (via retrospective analysis of historical data), post-intervention (six and twelve months after the intervention starts)

  2. The differences in the accuracy of different tuberculosis screening strategies between the intervention group and the control group

    The differences in the accuracy of different tuberculosis screening strategies between the intervention group and the control group, including sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, Youden index, and AUC

    Time frame: pre-intervention (via retrospective analysis of historical data), post-intervention (six and twelve months after the intervention starts)

07

Study locations

1 of 1 sites recruiting
  • Township Health-care settings in Yichang City
    Yichang, Hubei 443000, China
    Recruiting
08

References and documents

Publications

  • Yang X, Zhang H, Jiang W, Xin Y, Dai Z, Li Z, Xiong J, Sun R, Shao J, Yu J, Wang Y, Su X, Liu J, Li Z. Effectiveness of computer-aided detection chest X-ray screening for improving tuberculosis diagnostic yield in Chinese primary healthcare settings: study protocol for a prospective cluster randomised controlled trial. BMJ Open. 2026 Feb 4;16(2):e112124. doi: 10.1136/bmjopen-2025-112124. PubMed 41638733 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Gender, age, tuberculosis diagnosis situation, diagnosis delay situation, detection rate situation, AI accuracy

Supporting information: Study protocol, Statistical analysis plan

Time frame: January 2025 - December 2027

Access criteria: Personnel who have been approved by the research leader can access the declassified data

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

Of 169 non-industry interventional studies with no phase under Tuberculosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's planned 27 months is close to that.

Counting every sponsor, half of 171 studies reached it within 25 months; a quarter within 14 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 9, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06963606
Lead sponsor
Xuelin Yang
Collaborators
China Medical Board (CMB), Yichang Center for Disease Control and Prevention, China, JF Intelligent Healthcare Medical Technology Co
Responsible party
Xuelin Yang (Project researcher, Peking Union Medical College) — Sponsor-investigator
First posted
May 9, 2025
Start date
Sep 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

Yang Xuelin
Contact
yangxuelin321@163.com
0536-13964768397
Su Xiaoyou Prof
Contact
Wang Ye Prof
study chair · chool of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion